Featured Research

from universities, journals, and other organizations

Major bleeds rise with perioperative aspirin for non-cardiac surgery

Date:
March 31, 2014
Source:
American College of Cardiology
Summary:
Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin. At the same time, aspirin did not reduce incidence of post-operative heart attacks and death, according to new data.

Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin. At the same time, aspirin did not reduce incidence of post-operative heart attacks and death, according to data from POISE-2 presented at the American College of Cardiology's 63rd Annual Scientific Session. POISE-2 is the largest clinical trial focused on major cardiovascular complications in non-cardiac surgery.

Related Articles


Although many guidelines address prophylactic aspirin in a surgical setting, the focus is largely on cardiac surgery. Little guidance is available for patients undergoing non-cardiac surgery. This phase III trial followed earlier evidence suggesting that small doses of aspirin and clonidine can ward off heart attacks and heart-related death for such patients. Data for clonidine are to be presented separately at ACC.14.

POISE-2 enrolled 10,011 patients in 23 countries and grouped them by aspirin use: those who had been taking any dose daily for four of the six weeks before surgery, which became the continuation stratum, and those who had not, the initiation stratum. For the continuation stratum, aspirin use was stopped at least 72 hours before surgery. All patients received placebo or 200 mg aspirin just before surgery. The initiation stratum continued 100 mg aspirin or placebo daily for 30 days. The continuation stratum received 100 mg aspirin or placebo for seven days and then resumed their previous aspirin regimen. The primary endpoint of death and non-fatal heart attack at 30 days was no different between the two groups (7 percent in the aspirin group and 7.1 percent in the placebo group); however, major bleeding was significantly higher in aspirin-treated patients than in the placebo group (4.6 percent vs. 3.7 percent). The primary and secondary outcomes were similar in the two aspirin strata.

"POISE-2 demonstrated that adding aspirin on top of prophylactic anticoagulants in patients who are having non-cardiac surgery is not beneficial," said P.J. Devereaux, M.D., Ph.D., associate professor of clinical epidemiology and biostatistics at McMaster University, and lead investigator for the study. "An important caveat is that 65 percent of our patients were on prophylactic anticoagulants."

There is strong evidence that aspirin prevents perioperative blood clots in veins if an anticoagulant isn't given, he noted. No subgroup effects were seen for vascular versus non-vascular surgery or baseline risk according to the Revised Cardiac Risk Index.

With major bleeding known to increase the likelihood of post-surgical heart attack and a post-hoc POISE-2 regression analysis demonstrating this relationship, researchers considered why their study found a higher risk for bleeding but not for heart attack. "One possibility is that aspirin did prevent some heart attacks, but we were causing enough bleeding to nullify that benefit," Devereaux said. The study used clinical measurements for maximum reliability in identifying heart attacks, because symptoms are masked by pain-killing drugs in more than 50 percent of patients who have heart attacks after surgery.

According to data analysis, the absolute risk increase for life-threatening and major bleeding with aspirin treatment drops from about 1.2 percent on the day of surgery to 0.9 percent by day four and to 0.3 by day eight. At about the eighth day, the risk returns to normal. This information will help doctors weigh benefits versus potential risks when aspirin might be indicated post-surgically, Devereaux said.

"We're confirming a finding that bleeding itself can cause heart attacks," he said. "We need to find a better way to prevent bleeding so we can get back to how to prevent some of these thrombotic events." Patients will be followed for a year, and one-year data will be analyzed.

Although POISE-2 is a large trial by perioperative standards, the lower (0.86) and upper (1.15) boundary of the hazard ratio for the primary outcome identifies that the possibility of appreciable benefit or harm has not been excluded, Devereaux said.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "Major bleeds rise with perioperative aspirin for non-cardiac surgery." ScienceDaily. ScienceDaily, 31 March 2014. <www.sciencedaily.com/releases/2014/03/140331100135.htm>.
American College of Cardiology. (2014, March 31). Major bleeds rise with perioperative aspirin for non-cardiac surgery. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/03/140331100135.htm
American College of Cardiology. "Major bleeds rise with perioperative aspirin for non-cardiac surgery." ScienceDaily. www.sciencedaily.com/releases/2014/03/140331100135.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins